{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T02:13:32Z","timestamp":1755224012787,"version":"3.43.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiology Clinics"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ccl.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T22:47:00Z","timestamp":1728082020000},"page":"43-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Arrhythmia Challenges in Cardio-Oncology"],"prefix":"10.1016","volume":"43","author":[{"given":"Jonathan C.","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncology"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12916-024-03308-z","article-title":"Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors","volume":"22","author":"Park","year":"2024","journal-title":"BMC Med"},{"issue":"9","key":"10.1016\/j.ccl.2024.09.001_bib4","doi-asserted-by":"crossref","first-page":"e1911838","DOI":"10.1001\/jamanetworkopen.2019.11838","article-title":"Association of early-stage breast cancer and subsequent chemotherapy with risk of atrial fibrillation","volume":"2","author":"Abdel-Qadir","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of cardiology\/American heart association Joint Committee on clinical practice guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2024.09.001_bib6","doi-asserted-by":"crossref","first-page":"i4482","DOI":"10.1136\/bmj.i4482","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib7","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/mpo.2950050110","article-title":"Electrocardiographic changes following adriamycin treatment","volume":"5","author":"Dindogru","year":"1978","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ccl.2024.09.001_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.amjcard.2023.11.038","article-title":"Impact of atrial fibrillation on heart failure in patients treated with anthracycline chemotherapy","volume":"211","author":"Onoue","year":"2024","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.ccl.2024.09.001_bib10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/hon.3034","article-title":"Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines","volume":"40","author":"Diamond","year":"2022","journal-title":"Hematol Oncol"},{"issue":"9","key":"10.1016\/j.ccl.2024.09.001_bib11","doi-asserted-by":"crossref","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","article-title":"Drug-induced mitochondrial dysfunction and cardiotoxicity","volume":"309","author":"Varga","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"10.1016\/j.ccl.2024.09.001_bib12","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2005.04.6813","article-title":"Phase I to II study of pleurectomy\/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma","volume":"24","author":"Richards","year":"2006","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0167-8140(88)90296-4","article-title":"Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil","volume":"13","author":"Eskilsson","year":"1988","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"10","key":"10.1016\/j.ccl.2024.09.001_bib14","doi-asserted-by":"crossref","first-page":"e012798","DOI":"10.1136\/bmjopen-2016-012798","article-title":"Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer","volume":"6","author":"Polk","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ccl.2024.09.001_bib15","first-page":"93","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bmt.2009.97","article-title":"Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation","volume":"45","author":"Peres","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ccl.2024.09.001_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/ijc.34058","article-title":"Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer","volume":"151","author":"Forster","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ccl.2024.09.001_bib18","article-title":"Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide","author":"Riekhof","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib20","doi-asserted-by":"crossref","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib21","doi-asserted-by":"crossref","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.ccl.2024.09.001_bib22","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib23","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk factors for the development of atrial fibrillation on ibrutinib treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib24","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.26.4345","article-title":"Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr Oncol Tor Ont"},{"issue":"15","key":"10.1016\/j.ccl.2024.09.001_bib25","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ccl.2024.09.001_bib27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib28","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2352-3026(22)00320-9","article-title":"Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study","volume":"10","author":"Shadman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.ccl.2024.09.001_bib29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jaccao.2023.09.002","article-title":"Cardiovascular toxicities of BTK inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology state-of-the-art review","volume":"5","author":"Quartermaine","year":"2023","journal-title":"JACC CardioOncology"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10277","key":"10.1016\/j.ccl.2024.09.001_bib31","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet Lond Engl"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib32","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00280-011-1753-2","article-title":"Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma","volume":"69","author":"Petrini","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11912-016-0514-0","article-title":"Tyrosine kinase inhibitors and vascular toxicity: impetus for a classification system?","volume":"18","author":"Herrmann","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"10.1016\/j.ccl.2024.09.001_bib34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ccl.2024.09.001_bib35","doi-asserted-by":"crossref","first-page":"e029361","DOI":"10.1161\/JAHA.123.029361","article-title":"Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer","volume":"12","author":"Fradley","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"21","key":"10.1016\/j.ccl.2024.09.001_bib36","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor\u2013related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ccl.2024.09.001_bib37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.ccl.2024.09.001_bib38","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor t-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR t cell therapy: a retrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncology"},{"issue":"18","key":"10.1016\/j.ccl.2024.09.001_bib40","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor t-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib41","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2217\/imt-2022-0145","article-title":"Updated insights on cardiac risks of CD19-directed chimeric antigen receptor T-cell therapy: a pharmacovigilance study","volume":"15","author":"Zhai","year":"2023","journal-title":"Immunotherapy"},{"issue":"16","key":"10.1016\/j.ccl.2024.09.001_bib42","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/bloodadvances.2023009766","article-title":"Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma","volume":"7","author":"Lee","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.ccl.2024.09.001_bib43","doi-asserted-by":"crossref","first-page":"610915","DOI":"10.3389\/fcvm.2021.610915","article-title":"Cancer radiation therapy may be associated with atrial fibrillation","volume":"8","author":"Apte","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijrobp.2023.08.011","article-title":"Incident atrial fibrillation and survival outcomes in esophageal cancer following radiotherapy","volume":"118","author":"Miller","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib45","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jamaoncol.2022.4202","article-title":"Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer","volume":"8","author":"Kim","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ccl.2024.09.001_bib46","doi-asserted-by":"crossref","first-page":"110085","DOI":"10.1016\/j.radonc.2024.110085","article-title":"Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: an NI-HEART analysis","volume":"192","author":"Walls","year":"2024","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"41","key":"10.1016\/j.ccl.2024.09.001_bib47","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the European Hematology association (EHA), the European society for Therapeutic Radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ccl.2024.09.001_bib48","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib49","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"year":"2021","series-title":"Pediatric and Neonatal Lexi-drugs online","key":"10.1016\/j.ccl.2024.09.001_bib50"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib51","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00228-016-2120-3","article-title":"High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate","volume":"72","author":"Jamani","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ccl.2024.09.001_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/MAJ.0b013e31828a7656","article-title":"Efficacy and safety of ibutilide for chemical cardioversion of atrial fibrillation and atrial flutter in cancer patients","volume":"347","author":"Bickford","year":"2014","journal-title":"Am J Med Sci"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib53","first-page":"19","article-title":"Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer","volume":"9","author":"Ganatra","year":"2023","journal-title":"Cardio-Oncol Lond Engl"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10840-023-01677-8","article-title":"Safety and efficacy of catheter ablation for atrial fibrillation in cancer survivors: a systematic review and meta-analysis","volume":"67","author":"Costa","year":"2024","journal-title":"J\u00a0Interv Card Electrophysiol Int J Arrhythm Pacing"},{"issue":"12","key":"10.1016\/j.ccl.2024.09.001_bib55","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ccl.2024.09.001_bib56","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ccl.2024.09.001_bib57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjcard.2022.06.044","article-title":"Validation of embolic and bleeding risk scores in patients with atrial fibrillation and cancer","volume":"180","author":"Raposeiras-Roubin","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ccl.2024.09.001_bib58","article-title":"Patterns of anticoagulation use and all-cause of mortality in cancer patients with atrial fibrillation","author":"Han","year":"2023","journal-title":"Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"issue":"5","key":"10.1016\/j.ccl.2024.09.001_bib59","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaccao.2020.09.008","article-title":"Patterns of anticoagulation use in patients with cancer with atrial fibrillation and\/or atrial flutter","volume":"2","author":"Fradley","year":"2020","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.ccl.2024.09.001_bib60","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hjc.2023.06.005","article-title":"Risk of arterial thromboembolism, bleeding and mortality in atrial fibrillation patients with comorbid cancer: a systematic review and meta-analysis","volume":"74","author":"Balomenakis","year":"2023","journal-title":"Hell J Cardiol HJC Hell Kardiologike Epitheorese"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib61","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"23","key":"10.1016\/j.ccl.2024.09.001_bib62","doi-asserted-by":"crossref","first-page":"e026388","DOI":"10.1161\/JAHA.121.026388","article-title":"Performance of the HAS-BLED, ORBIT, and ATRIA bleeding risk scores on a cohort of 399 344 hospitalized patients with atrial fibrillation and cancer: data from the French National Hospital Discharge Database","volume":"11","author":"Pastori","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib63","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"Lip","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ccl.2024.09.001_bib64","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"issue":"16","key":"10.1016\/j.ccl.2024.09.001_bib65","doi-asserted-by":"crossref","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 Trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"9","key":"10.1016\/j.ccl.2024.09.001_bib66","first-page":"706","article-title":"Superior safety of direct oral anticoagulants compared to Warfarin in patients with atrial fibrillation and underlying cancer: a national veterans affairs database study","volume":"16","author":"Sawant","year":"2019","journal-title":"J\u00a0Geriatr Cardiol JGC"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib67","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis","volume":"51","author":"Mariani","year":"2021","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s11239-021-02570-9","article-title":"Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation","volume":"53","author":"Wang","year":"2022","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.17925\/HI.2023.17.1.54","article-title":"Peri- and post-procedural anticoagulation with left atrial appendage occlusion devices","volume":"17","author":"Agasthi","year":"2023","journal-title":"Heart Int"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib71","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaccao.2022.10.016","article-title":"Left atrial appendage occlusion in patients with atrial fibrillation and cancer","volume":"5","author":"Shabtaie","year":"2023","journal-title":"JACC CardioOncology"},{"issue":"8","key":"10.1016\/j.ccl.2024.09.001_bib72","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s10840-023-01621-w","article-title":"Outcomes of patients with cancer undergoing percutaneous left atrial appendage occlusion","volume":"66","author":"Agarwal","year":"2023","journal-title":"J\u00a0Interv Card Electrophysiol Int J Arrhythm Pacing"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib73","first-page":"39","article-title":"Utilization and short-term outcomes of percutaneous left atrial appendage occlusion in patients with cancer","volume":"9","author":"Zhang","year":"2023","journal-title":"Cardio-Oncol Lond Engl"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib74","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jacep.2016.03.001","article-title":"Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators","volume":"3","author":"Enriquez","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"10.1016\/j.ccl.2024.09.001_bib75","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/CAD.0b013e328012d023","article-title":"QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines","volume":"18","author":"Arbel","year":"2007","journal-title":"Anti Cancer Drugs"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib76","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V","article-title":"Acute arrhythmogenicity of doxorubicin administration","volume":"60","author":"Steinberg","year":"1987","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacep.2016.08.009","article-title":"Burden of cardiac arrhythmias in patients with anthracycline-related cardiomyopathy","volume":"3","author":"Mazur","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"10.1016\/j.ccl.2024.09.001_bib78","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/j.1742-1241.2007.01323.x","article-title":"5-fluorouracil increases the number and complexity of premature complexes in the heart: a prospective study using ambulatory ECG monitoring","volume":"61","author":"Yilmaz","year":"2007","journal-title":"Int J Clin Pract"},{"issue":"10","key":"10.1016\/j.ccl.2024.09.001_bib79","first-page":"e30489","article-title":"Diagnosis and management of a patient with 5-fluorouracil-induced st elevation and nonsustained ventricular tachycardia as a late presentation of cardiotoxicity and successful 5-fluorouracil rechallenge","volume":"14","author":"Medepalli","year":"2022","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib80","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jemermed.2015.09.001","article-title":"A\u00a0case of 5-fluorouracil-induced cardiac arrest","volume":"50","author":"Ray","year":"2016","journal-title":"J\u00a0Emerg Med"},{"issue":"8","key":"10.1016\/j.ccl.2024.09.001_bib81","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2459\/01.JCM.0000237914.12915.dd","article-title":"Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin","volume":"7","author":"Hrovatin","year":"2006","journal-title":"J\u00a0Cardiovasc Med Hagerstown Md"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib82","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"de Forni","year":"1992","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib83","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/oncolo\/oyab035","article-title":"Cardiotoxicity from capecitabine chemotherapy: prospective study of incidence at rest and during physical exercise","volume":"27","author":"Lestuzzi","year":"2022","journal-title":"Oncol"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib84","first-page":"1542","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib85","first-page":"132","article-title":"Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm","volume":"18","author":"Shah","year":"2012","journal-title":"J\u00a0Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib86","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"18","key":"10.1016\/j.ccl.2024.09.001_bib87","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","article-title":"United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia","volume":"19","author":"Soignet","year":"2001","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"19","key":"10.1016\/j.ccl.2024.09.001_bib88","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","article-title":"Effect of arsenic trioxide on QT interval in patients with advanced malignancies","volume":"21","author":"Barbey","year":"2003","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib89","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-133-11-200012050-00012","article-title":"Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia","volume":"133","author":"Ohnishi","year":"2000","journal-title":"Ann Intern Med"},{"issue":"18","key":"10.1016\/j.ccl.2024.09.001_bib90","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib91","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.ccl.2024.09.001_bib92","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib93","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"issue":"18","key":"10.1016\/j.ccl.2024.09.001_bib94","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib95","doi-asserted-by":"crossref","first-page":"e002007","DOI":"10.1136\/jitc-2020-002007","article-title":"Electrocardiographic features of immune checkpoint inhibitor associated myocarditis","volume":"9","author":"Zlotoff","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ccl.2024.09.001_bib96","first-page":"131","article-title":"The association of cardiac arrhythmias with chimeric antigen receptor T cell therapy in hospitalised patients: insights from National Inpatient Sample","volume":"174","author":"Thotamgari","year":"2022","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib97","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/jamaoncol.2022.4194","article-title":"Association of QTc formula with the clinical management of patients with cancer","volume":"8","author":"Richardson","year":"2022","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ccl.2024.09.001_bib98","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","article-title":"The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview","volume":"23","author":"Giraud","year":"2022","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib99","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.CIR.88.2.782","article-title":"Diagnostic criteria for the long QT syndrome. An update","volume":"88","author":"Schwartz","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2024.09.001_bib100","doi-asserted-by":"crossref","first-page":"753443","DOI":"10.3389\/fpubh.2021.753443","article-title":"Cost-effectiveness of portable electrocardiogram for screening cardiovascular diseases at a primary health center in Ahmedabad District, India","volume":"9","author":"Shah","year":"2021","journal-title":"Front Public Health"},{"issue":"8","key":"10.1016\/j.ccl.2024.09.001_bib101","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ccl.2024.09.001_bib102","doi-asserted-by":"crossref","first-page":"613625","DOI":"10.3389\/fcvm.2021.613625","article-title":"QT prolongation in cancer patients","volume":"8","author":"Kim","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib103","doi-asserted-by":"crossref","first-page":"102241","DOI":"10.1016\/j.cpcardiol.2023.102241","article-title":"The pivotal role of compelling high-risk electrocardiographic markers in prediction of ventricular arrhythmic risk in arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis","volume":"49","author":"Iqbal","year":"2024","journal-title":"Curr Probl Cardiol"},{"issue":"14","key":"10.1016\/j.ccl.2024.09.001_bib104","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"Al-Khatib","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.ccl.2024.09.001_bib105","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the American Heart Association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib106","first-page":"465","article-title":"Clinical outcome in patients with implantable cardioverter-defibrillator and cancer: a nationwide study","volume":"21","author":"Christensen","year":"2019","journal-title":"Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol"},{"issue":"18","key":"10.1016\/j.ccl.2024.09.001_bib107","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1001\/jama.2019.16658","article-title":"Association of cardiac resynchronization therapy with change in left ventricular ejection fraction in patients with chemotherapy-induced cardiomyopathy","volume":"322","author":"Singh","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ccl.2024.09.001_bib108","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.hrthm.2021.02.017","article-title":"Arrhythmias and device therapies in patients with cancer therapy-induced cardiomyopathy","volume":"18","author":"Lee","year":"2021","journal-title":"Heart Rhythm"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib109","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.hlc.2018.09.011","article-title":"Current device therapies for sudden cardiac death prevention - the ICD, subcutaneous ICD and wearable ICD","volume":"28","author":"Chieng","year":"2019","journal-title":"Heart Lung Circ"},{"issue":"13","key":"10.1016\/j.ccl.2024.09.001_bib110","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ccl.2024.09.001_bib111","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.amjcard.2003.12.061","article-title":"Bradycardia during therapy for multiple myeloma with thalidomide","volume":"93","author":"Fahdi","year":"2004","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.ccl.2024.09.001_bib112","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMoa053583","article-title":"Thalidomide and hematopoietic-cell transplantation for multiple myeloma","volume":"354","author":"Barlogie","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ccl.2024.09.001_bib113","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2021.08.014","article-title":"ALK inhibitor-induced bradycardia: a systematic-review and meta-analysis","volume":"161","author":"Cirne","year":"2021","journal-title":"Lung Cancer Amst Neth"},{"issue":"7","key":"10.1016\/j.ccl.2024.09.001_bib114","first-page":"1233","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J\u00a0Thorac Oncol Off Publ Int Assoc Study Lung Cancer"},{"issue":"3","key":"10.1016\/j.ccl.2024.09.001_bib115","doi-asserted-by":"crossref","first-page":"e000219","DOI":"10.1136\/esmoopen-2017-000219","article-title":"Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced\/metastatic ALK-positive non-small-cell lung cancer","volume":"2","author":"Blackhall","year":"2017","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ccl.2024.09.001_bib116","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jaccao.2022.09.006","article-title":"Cardiac toxicity of alectinib in patients with ALK+ lung cancer: outcomes of cardio-oncology follow-up","volume":"5","author":"Pruis","year":"2023","journal-title":"JACC CardioOncology"},{"issue":"5","key":"10.1016\/j.ccl.2024.09.001_bib117","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1759-7714.14769","article-title":"High incidence and reversible bradycardia events following alectinib initiation","volume":"14","author":"Yuan","year":"2023","journal-title":"Thorac Cancer"},{"issue":"11","key":"10.1016\/j.ccl.2024.09.001_bib118","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/1078-0432.CCR-14-3157","article-title":"FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer","volume":"21","author":"Khozin","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ccl.2024.09.001_bib119","first-page":"1","article-title":"Crizotinib inhibits hyperpolarization-activated cyclic nucleotide-gated channel 4 activity","volume":"3","author":"Zhang","year":"2017","journal-title":"Cardio-Oncol Lond Engl"},{"issue":"15","key":"10.1016\/j.ccl.2024.09.001_bib120","first-page":"117","article-title":"A\u00a0reassessment of cardiac toxicity associated with Taxol","author":"Arbuck","year":"1993","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"12","key":"10.1016\/j.ccl.2024.09.001_bib121","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.1993.11.12.2405","article-title":"Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103","volume":"11","author":"Trimble","year":"1993","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.ccl.2024.09.001_bib122","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1200\/JCO.1991.9.9.1704","article-title":"Cardiac disturbances during the administration of taxol","volume":"9","author":"Rowinsky","year":"1991","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"10.1016\/j.ccl.2024.09.001_bib123","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0167-5273(93)90027-E","article-title":"Associated cardiac lesions in patients with radiation-induced complete heart block","volume":"39","author":"Orzan","year":"1993","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.ccl.2024.09.001_bib124","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1540-8159.1991.tb02842.x","article-title":"Complete atrioventricular block following mediastinal irradiation: a report of six cases","volume":"14","author":"Slama","year":"1991","journal-title":"Pacing Clin Electrophysiol PACE"},{"key":"10.1016\/j.ccl.2024.09.001_bib125","first-page":"100936","article-title":"Risk of pacemaker implantation after radiotherapy for breast cancer: a study based on French nationwide health care database sample","volume":"38","author":"Errahmani","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"10.1016\/j.ccl.2024.09.001_bib126","first-page":"e382","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ccl.2024.09.001_bib127","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes","year":"2019","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.ccl.2024.09.001_bib128","first-page":"880","article-title":"Pacemaker therapy in very elderly patients: survival and prognostic parameters of single center experience","volume":"16","author":"Marini","year":"2019","journal-title":"J\u00a0Geriatr Cardiol JGC"},{"issue":"10","key":"10.1016\/j.ccl.2024.09.001_bib129","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1016\/j.hrthm.2015.06.003","article-title":"Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy","volume":"12","author":"Brambatti","year":"2015","journal-title":"Heart Rhythm"}],"container-title":["Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865124000870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733865124000870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T10:35:43Z","timestamp":1754994943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733865124000870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":128,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0733865124000870"],"URL":"https:\/\/doi.org\/10.1016\/j.ccl.2024.09.001","relation":{},"ISSN":["0733-8651"],"issn-type":[{"type":"print","value":"0733-8651"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arrhythmia Challenges in Cardio-Oncology","name":"articletitle","label":"Article Title"},{"value":"Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccl.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}